Stromectol is the original brand name under which ivermectin was approved for human use, developed by Merck and licensed in the United States in 1996. Every other human ivermectin tablet on the market is a generic. The practical question — whether the brand is meaningfully better — has a clear regulatory answer and a more nuanced real-world one.
A generic is not simply a copy that someone asserts is equivalent. To be approved it must demonstrate bioequivalence: that it delivers the same active ingredient to the bloodstream at the same rate and to the same extent as the reference product.
This is established with a pharmacokinetic study in human volunteers, usually crossover in design. Regulators require the 90% confidence interval for the ratio of key measures — peak concentration and total exposure — to fall within 80% to 125% of the reference product.
That range is frequently misread as "a generic can be 20% weaker". It is a statistical confidence requirement on the whole interval, not a licence for a 20% deviation. In practice approved generics cluster very close to the reference, typically within a few percent.
| Aspect | Must match? |
|---|---|
| Active ingredient | Yes — same molecule, same amount |
| Strength and dosage form | Yes |
| Route of administration | Yes |
| Rate and extent of absorption | Yes, within bioequivalence limits |
| Inactive ingredients | No — may differ |
| Tablet colour, shape, markings | No |
| Manufacturer | No |
Excipient differences are the main source of genuine variation between products. They rarely affect efficacy, but they can matter for someone with a specific sensitivity, and they occasionally affect tolerability.
The meaningful variable is not brand versus generic. It is the quality of the specific manufacturer. A generic from a well-run GMP facility with strong quality control is equivalent to the brand in every way that matters. A product from a facility with weak controls may not be, regardless of what the packaging claims.
This is why the manufacturer name, batch number and GMP status are more informative than whether a box says Stromectol. Regulatory inspection records are public in most jurisdictions, and a supplier who can name the manufacturer is giving you something you can check.
Stromectol-branded product has become scarce in several markets as generic supply expanded. In much of the world the practical choice is between generics rather than between brand and generic.
Generics are typically far less expensive. The price gap reflects development and marketing costs rather than manufacturing quality — the originator carries the cost of the original research and the registration trials, which a generic does not repeat.
GMP-certified human formulations — tablets and 1% cream. Never veterinary products. Most USA orders ship within 1–7 business days, with tracking on every order.
View products and pricingAn approved generic must demonstrate bioequivalence in human volunteers, meaning it delivers the same active ingredient to the bloodstream at the same rate and extent. Where that standard has been met, yes. The variable worth attention is the quality of the specific manufacturer, not the brand name.
No. It is a requirement that the 90% confidence interval for the ratio against the reference product falls within that range, which is a considerably stricter test than it sounds. Approved generics typically sit within a few percent of the reference.
Tablet appearance is often protected by trade dress, so generics deliberately differ in colour, shape and markings. Appearance carries no information about potency.
Branded supply has become limited in a number of markets as generics expanded. In much of the world the realistic choice is between generic manufacturers rather than between brand and generic.
Look for a named manufacturer, GMP certification, a printed batch number and expiry, and sealed manufacturer packaging. A supplier who cannot tell you who made the product cannot tell you anything useful about its quality.